Skip to content
thestock.space

Syngene International (SYNGENE) had a P/E of 90.3× on 6 Nov 2026, above the industry P/E of 52.8×, and the shares are 39% below their 52-week high. Sales grew 5.4% a year over 3 years while net profit fell 12%; its ROCE of 8.3% is the lowest among the 7 largest Diagnostics & Research peers. Debt is 0.10× equity, and its dividend yield is 0.3%. It is a small-cap company with a market cap of ₹16,772 Cr, ranked 3rd of 18 Diagnostics & Research companies by market cap; the shares fell 36% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹412.15
Day high
₹418.35
Day low
₹408.15
Prev. close
₹414.10
Volume
10.2 L

Health check

1 fair · 5 to check
  • ReturnsBehind

    −36.0% over a year, better than 0 of 7 peers.

  • Price tagPricier

    P/E 90.3 vs industry 52.8.

  • GrowthSlow

    Sales +5.4%, profit −12.0% a year over 3 years.

  • ProfitabilityWeak

    ROCE 8.3% vs peer median 19.1%.

  • Balance sheetFair

    Debt 0.10× equity, interest covered 10.2×, Piotroski 5 of 9.

  • Red flags5 to check

    Return on equity is low at 3.9%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Diagnostics & Research

17 listed peers. Screen the industry

Small cap

₹16,772 Cr, #3 of 18 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹3,522 Cr · profit ₹186 Cr
Market cap
₹16,772 Cr
Small cap
P/E
90.3
Industry 52.8
Price to book
3.46
Peers 11.99
Dividend yield
0.30%
ROE
3.9%
Peers 17.7%
ROCE
8.3%
Peers 19.1%
Debt to equity
0.10
Debt ₹507 Cr
EPS (TTM)
₹4.62
Face value ₹10
OPM (TTM)
21.3%
Net margin 5.3%
Sales growth
−8.6%
Latest quarter vs a year ago
Profit growth
−52.1%
Latest quarter vs a year ago
Price to sales
4.76
EV/EBITDA 19.6

Strengths and risks

Strengths

  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 3.9%.
  • Quarterly profit down 52.1% on a year ago.
  • Quarterly sales down 8.6% on a year ago.
  • P/E of 90.3 against an industry P/E of 52.8.
  • 39% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Syngene International

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of…

Headquarters
Bengaluru
Employees
6,692
Sector
Healthcare
ISIN
INE398R01022
Website
syngeneintl.com

Price range

52 weeks

₹344.45₹678.95

Today

₹408.15₹418.35
Avg volume (3M)
12.9 L
1-year return
minus 36.0%
From 52-week high
minus 38.5%

Analyst consensus

8 analysts
BuyMean target ₹510.00 plus 22.2%

Target range, with today’s price

Low ₹400.00High ₹735.00

Next results expected around 20 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Diagnostics & Research

Compare with peersScreen the whole industry
Company
SAILIFESai Life Sciences1,785.10plus 11.95%37,929101.515.2218.1%15.1%28.7%21.3%226.8%0.00%plus 72.7%
LALPATHLABDr. Lal Path Labs1,970.00plus 0.16%32,94156.511.9925.7%22.6%30.2%11.1%28.3%1.02%plus 24.7%
SYNGENESyngene International417.30plus 0.77%16,77290.33.468.3%3.9%25.7%5.4%−12.0%0.30%minus 36.0%
VIJAYAVijaya Diagnostic Centre1,468.60plus 2.15%15,12674.414.2919.1%21.2%43.1%21.0%26.9%0.14%plus 40.2%
METROPOLISMetropolis Healthcare568.75minus 0.39%11,80352.87.1715.7%14.6%21.7%12.7%10.0%0.35%plus 12.5%
THYROCAREThyrocare Technologies493.10plus 0.68%7,84855.014.7533.8%26.4%32.2%16.7%36.2%1.89%plus 8.3%
VIMTALABSVimta Labs496.45minus 2.14%2,21927.94.5221.0%17.7%34.7%8.9%17.2%0.40%minus 23.3%
SURAKSHASuraksha Diagnostic333.55plus 0.68%1,73748.57.0714.7%14.1%21.8%17.7%70.3%0.15%plus 2.2%
Median of 7 peers–0.68%11,80355.011.9919.1%17.7%30.2%16.7%28.3%0.35%12.5%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26Sep 26
875–9171,037736833
650–763712633664
22494.8154325103169
25.6%–16.8%31.3%13.9%20.3%
0–70.61.113.56.7
11.6–11.912.19.610
111–114112112112
––−70.6−6−13.5−6.7
101–28.4196−19.247
14.4%–47.2%24.5%53.1%31.5%
86.7–15148−932.2
2.15–0.373.67-0.220.80

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+5.4%
Profit CAGR 3Y
−12.0%
EPS CAGR 3Y
−11.9%
ROE
3.9%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3,0803,3703,5133,611
–+9.4%+4.3%+2.8%
2,0962,2972,4672,601
9851,0731,0461,010
32.0%31.8%29.8%28.0%
7.818.650.2−3.7
34.545.149.244.8
367426433453
2.10.245.5−97.9
594621660411
21.8%17.8%24.8%22.9%
464510496317
–+9.8%minus 2.7%minus 36.2%
11.5112.6912.347.87

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
401402403403
3,2173,8564,3244,436
815555578458
1,3981,3391,4911,757
5,8316,1526,7967,055
2,7933,6254,0313,976
1928441,2891,046
21934.938560
1,3541,0771,3971,289
1,27357041184
5,8316,1526,7967,055

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
8241,0421,168915
−656−496−745−860
−343−551−142−215
−175−4.9281−160
−518−511−770−368
305531398547
−40.1−50.3−50.3−50.4

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 38.5% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you